Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder
Jazayeri S, Tehrani-Doost M, Keshavarz SA, Hosseini M, Djazayery A, Amini H, Jalali M, Peet M
The Australian and New Zealand journal of psychiatry · 147 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2008-01-01 · Aust N Z J Psychiatry · vol. 42 · número 3 · págs. 192–198
- Editorial
- SAGE Publishing
- Citado
- 215 citas · más que el 99% de estudios similares · 11.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 40 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Treatment of Major Depression · Tryptophan and brain disorders
- Palabras clave
- eicosapentaenoic acid, omega-3 fatty acids, fluoxetine, major depressive disorder, combination therapy, antidepressant efficacy, Hamilton Depression Rating Scale
- MeSH
- humans, fluoxetine, eicosapentaenoic acid, antidepressive agents, drug therapy, combination, severity of illness index, double-blind method, diagnostic and statistical manual of mental disorders, adult, female, male, surveys and questionnaires, major depressive disorder
8 autores
- Shima Jazayeri🇮🇷 · autor de correspondenciaRoozbeh Hospital; Tehran University of Medical Sciences
- Mehdi Tehrani‐Doost🇮🇷 · autor de correspondenciaTehran University of Medical Sciences
- Seyed Ali Keshavarz🇮🇷 · autor de correspondenciaRoozbeh Hospital; Tehran University of Medical Sciences
- Mostafa Hosseini🇮🇷Tehran University of Medical Sciences
- Abolghassem Djazayery🇮🇷 · autor de correspondenciaRoozbeh Hospital; Tehran University of Medical Sciences
- Homayoun Amini🇮🇷Tehran University of Medical Sciences
- Mahmoud Jalali🇮🇷 · autor de correspondenciaRoozbeh Hospital; Tehran University of Medical Sciences
- Malcolm Peet
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
To compare therapeutic effects of eicosapentaenoic acid (EPA), fluoxetine and a combination of them in major depression.
Method
Sixty outpatients with a diagnosis of major depressive disorder based on DSM-IV criteria and a score >or=15 in the 17-item Hamilton Depression Rating Scale (HDRS) were randomly allocated to receive daily either 1000 mg EPA or 20 mg fluoxetine, or their combination for 8 weeks. Double dummy technique was used to double blind the study. Patients were assessed at 2 week intervals. Change in HDRS was the primary outcome measure.
Results
Analysis of covariance for HDRS at week 8 across treatment groups was performed in 48 patients who completed at least 4 weeks of the study, with the last observation carried forward. Treatment, age of onset and baseline HDRS had a significant effect on HDRS at week 8. EPA + fluoxetine combination was significantly better than fluoxetine or EPA alone from the fourth week of treatment. Fluoxetine and EPA appear to be equally effective in controlling depressive symptoms. Response rates (>or=50% decrease in baseline HDRS) were 50%, 56% and 81% in the fluoxetine, EPA and combination groups, respectively.
Conclusions
In the present 8 week trial EPA and fluoxetine had equal therapeutic effects in major depressive disorder. EPA + fluoxetine combination was superior to either of them alone.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.